Congratulations to Inga Hofmann, MD, Principal Investigator, and Emery Bresnick, Co-Principal Investigator, for their one-year, $200,000 grant from the Edward P. Evans Foundation, for the project, “Prognostic Markers and Therapeutic Targets in GATA2-Related Myelodysplastic Syndromes.” In this study, a team involving a laboratory scientist who is a GATA-2 expert (Bresnick) and a clinical scientist that treats children with MDS and leukemia (Hofmann), will combine efforts to better understand how GATA-2 functions and how it causes MDS and leukemia. Myelodysplastic syndrome (MDS) is a disease that keeps the body from properly producing enough healthy blood cells. We aim to use our unique expertise to discover prognostic markers and targets for new therapies to improve the outcomes of patients with MDS.